Refining metformin prescribing in New Zealand.

Metformin is the mainstay of treatment of type 2 diabetes. However, there has been significant concern on prescribing metformin in patients with renal impairment as a result of metformin-associated lactic acidosis (MALA). Recent studies have cast doubt on the existence of MALA purely related to metformin use. Medsafe recently initiated changes to datasheet so lower doses of metformin could be used in patients with GFR down to 15ml/min. In this paper we outline the context and implications of this change.

First national audit of the outcomes of care in young people with diabetes in New Zealand: high prevalence of nephropathy in Maori and Pacific Islanders.

BACKGROUND: Diabetes is an important cause of morbidity and mortality amongst young people. Despite improvements in technology, maintenance of good glycaemic control is hard to achieve. METHODS: In July 2003, 12 paediatric and adult hospital-based diabetes services across New Zealand were invited to take part in an audit of the process and outcomes of care. By March 2004, 9 centres had submitted data on 1282 (1117 with Type 1 diabetes, 105 with Type 2) children and young people born after 1 January 1978. RESULTS: There were significant centre differences in terms of glycaemic control, rates of microvascular complications and complication screening. The group mean HbA1c was 9.1 plus and minus 0.3%. Amongst 789 people aged 16-25 years, the prevalence of retinopathy was 12.8% (range 0-26%); nephropathy was 17.1% (range 7-28 %). Of those with a duration of diabetes <10 years, 25% had retinopathy and 27% nephropathy. Over the age of 12, microalbuminuria was more common amongst Maori and Pacific Islanders (43.8%) compared to Europeans (17%) or Others (17.8%). This was independent of the type of diabetes. CONCLUSIONS: This is the largest study of young people with diabetes undertaken in New Zealand. The results confirm the difficulty of achieving good glycaemic control in children and young adults. Microvascular complications were common, particularly in those of long duration, and cardiovascular risk factors were present in many young adults. The difference in average HbA1c% between centres was highly significant and independent of other factors. Type 2 diabetes mellitus in young people was associated with early onset nephropathy and dyslipidaemia (almost from diagnosis), thus suggesting the need for earlier diagnosis.

Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the HDDRISC study.

OBJECTIVE: To evaluate prediction of coronary heart disease (CHD) by quantitative measures of the metabolic syndrome and inflammation in a cohort of high socio-economic status males. METHODS: Incident CHD was identified in a cohort of 649 male participants in a company health programme during a mean follow-up of 10.6 years. Using factor analysis, metabolic syndrome and sub-clinical inflammation scores were derived from baseline measurements, which included an oral glucose tolerance test-derived measure of insulin resistance. Factor scores were then included as predictor variables in a Cox regression analysis of incident CHD. RESULTS: Forty-two cases of definite CHD were identified on follow-up. The conventional risk factors, cigarette smoking, blood pressure, total cholesterol and low HDL cholesterol were clearly distinguished as significant predictors of incident CHD. Erythrocyte sedimentation rate was also an independent predictor (coefficient 0.0480, z score 2.39, p=0.017). The metabolic syndrome factor included insulin resistance, body mass index, serum triglycerides, glucose tolerance, serum uric acid and fasting plasma glucose. The inflammation factor included serum globulin, blood leukocyte count, low albumin, haemoglobin and cholesterol, but not erythrocyte sedimentation rate. The inflammation factor score was a significant predictor of CHD (coefficient 0.4601, z score 2.43, p=0.015) but the metabolic syndrome factor was not (coefficient 0.2488, z score 1.24, p=0.2). CONCLUSIONS: Erythrocyte sedimentation rate and a factor analysis-derived measure of sub-clinical inflammation were important in the development of CHD in this relatively low-risk group, but neither metabolic syndrome factor score nor its individual components predicted CHD.